Mizuho maintains Neutral on Albemarle, cuts target to $185

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

Mizuho analyst John Roberts maintains a Neutral rating on Albemarle and lowers the price target from $205 to $185.

powered bylight_fuzz_icon
44459919

*this image is generated using AI for illustrative purposes only.

Mizuho analyst John Roberts has maintained a Neutral rating on Albemarle while lowering the price target to $185 from $205. The adjustment reflects a revised outlook for the company's stock performance.

The previous price target stood at $205 before this reduction. Albemarle operates under the ticker symbol ALB on the NYSE.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific factors led Mizuho to revise Albemarle's outlook?

How might this price target reduction impact investor sentiment toward ALB?

What are the potential risks or opportunities for Albemarle in the current market?

like19
dislike

Citigroup upgrades Albemarle to Buy, keeps target at $225

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

Citigroup analyst Patrick Cunningham upgraded Albemarle from Neutral to Buy while maintaining the price target at $225.

powered bylight_fuzz_icon
43357342

*this image is generated using AI for illustrative purposes only.

Citigroup analyst Patrick Cunningham has upgraded Albemarle from Neutral to Buy, maintaining the price target at $225. The rating change reflects a more positive outlook on the stock's performance potential.

The price target remains unchanged at $225, indicating the firm's valuation expectations for the company. Albemarle is listed on the NYSE under the ticker symbol ALB.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific factors drove Citigroup's more positive outlook on Albemarle's performance?

How might Albemarle's recent operational developments influence its ability to meet the $225 price target?

What are the potential risks to Albemarle's stock performance despite the upgrade?

like19
dislike